Advertisement

Abstract

Tumours arising from the pigmented components of skin, mucous membranes and the choroid of the eye, collectively known as the melanomas, have over the years stimulated a tremendous amount of interest in biologists, clinicians and pathologists for a variety of reasons. These rather striking and usually well recognizable lesions have caused controversy from the point of view of the origin of the cells in question embryologically and histogenetically and in the very nature of the neoplasms that arise in them. On one hand they represent one of the commonest neoplastic processes known to man, namely the benign pigmented moles and naevi (Fig. 1), and on the other a highly variable and often extremely malignant tumour whose ability to metastasize widely throughout the body has few rivals in the field of oncology (Pack, 1948; Ewing, 1922). It is, therefore, an ideal group of tumours in which to study the relationships between immune mechanisms and neoplasia, since the advantages of having such a wide spectrum of biological activity are considerable. Added to this one can study such superficial and easily observed tumours from their earliest appearance to the very wide spread metastatic disease that they often represent ultimately.

Fig. 1

Fig.1. Benign pigmented mole (junctional naevus). The precursor of malignant melanoma

Keywords

Melanoma Cell Human Malignant Melanoma Cellular Immunity Bacillus Calmette Guerin Spontaneous Regression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Algire, G. H., Legallais, F. Y.: Growth and vascularization of transplanted mouse melanomas. The biology of melanomas. N. Y. Acad. Sci. IV, 159–166 (1948).Google Scholar
  2. Allen, A. C., Spitz, S.: Malignant melanoma — A clinicopathological analysis of the criteria for prognosis and diagnosis. Cancer (Philad.) 6, 1–45 (1953).Google Scholar
  3. Arpels, C., Southam, C. M.: Cytotoxicity of sera from healthy persons and cancer patients. Int. J. Cancer 4, 548–559 (1969).PubMedGoogle Scholar
  4. Avis, P., Lewis, M. G.: Tumour associated fetal antigens in human tumours. J. nat. Cancer Inst. 51, 1063–1066 (1973).PubMedGoogle Scholar
  5. Baldwin, R. W.: Immunity to methyl cholanthrene induced tumours in inbred rats following atrophy and regression of the implanted tumours. Brit. J. Cancer 9, 652–657(1955).PubMedGoogle Scholar
  6. Bailly, C.: L’Histopronostic Du melanome malin cutoane. Thesis. Lyon: Association Corporative des Etudiants en Médecine de Lyon 1972.Google Scholar
  7. Bluming, A. Z., Vogel, C. L., Ziegler, J. L., Kiryabwire, J. W. M.: Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma - A second look. J. nat. Cancer Inst. 48, 17–24 (1972).PubMedGoogle Scholar
  8. Bodenham, D. C.: A study of 650 observed malignant melanomas in the South West Region. Ann. roy. Coll. Surg. Engl. 43, 218 (1968).Google Scholar
  9. Bodenham, D. C.: Basic principles of surgery — malignant melanoma, melanoma, and skin cancer. Proc. of the Int. Cancer Conf., Sydney, Australia, p. 375–387. Sydney, N. S. Wales: V. C. N. Blight Government Printers 1972.Google Scholar
  10. Brandes, L. J., Galton, D. A. G., Wiltshaw, E.: New approach to immunotherapy of melanoma. Lancet 1971 II, 293–295.Google Scholar
  11. Burdick, K. H., Hawk, W. A.: Vitiligo in a case of vaccinia virus-treated melanoma. Cancer (Philad.) 17, 708–712 (1964).Google Scholar
  12. Carswell, R.: Melanoma — pathological anatomy, part 9. London: Longman 1838.Google Scholar
  13. Catalona, W. J., Sample, W. F., Chretien, P. B.: Lymphocyte reactivity in cancer patients: correlation with tumour histology and clinical stage. Cancer (Philad.) 31, 65–71 (1973)Google Scholar
  14. Cloudman, A. M.: The effect of an extra chromosomal influence upon transplanted spontaneous tumours in mice. Science 93, 380–381 (1941).PubMedGoogle Scholar
  15. Clark, W. H.: A classification of malignant melanoma in man correlated with histogenesis and biological behaviour. Advances in biology of skin, 8. London: Pergamon Press 1967.Google Scholar
  16. Clark, W. H.: Personal communication (1973)Google Scholar
  17. Clark, W. H., Mihm, M. C.: Lentigo maligna and lentigo maligna melanoma. Amer. J. Path. 55, 39 (1969).PubMedGoogle Scholar
  18. Cochran, A. J.: Malignant melanoma. M. D. Thesis — University of Glasgow, p. 1–2 (1965).Google Scholar
  19. Cochran, A. J., Cochran, K.: Naevi of childhood (Abstract). Intern. Cancer Conf., Sydney, Australia (1972).Google Scholar
  20. Cochran, A. J., Jehn, V. W., Gothoska, B. P.: Cell mediated immunity to malignant melanoma. Lancet 1972I, 1340–1341.Google Scholar
  21. Coley, W. B., Hoguet, J. P.: Melanotic cancer. Ann. Surg. 64, 206–241 (1916).PubMedGoogle Scholar
  22. Coons, A. H., Kaplan, M. H.: Localization of antigens in tissue cells. II. Improvement in the method for the detection of antigens by means of fluorescent antibody. J. exp. Med. 91, 1 (1950).PubMedGoogle Scholar
  23. Coote, H.: Melanosis. Lancet 1846 II, 142–144.Google Scholar
  24. Copeman, P. W. M., Lewis, M. G., Bleehan, S. S.: Biology and immunology of Vitiligo and cutaneous malignant melanoma. Recent Advances in Dermatology (in press) (1972).Google Scholar
  25. Couperus, M., Rucker, R. C.: Histopathological diagnosis of malignant melanoma. Med. J. Aust. — Correspondence 2, 1028 (1954).Google Scholar
  26. Currie, G. A.: Proc. of Paris Cancer Symposium (in press) (1972).Google Scholar
  27. Currie, G. A., Lejeune, F., Hamilton-Fairley, G.: Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Brit. med. J. 1971 II, 305–310.Google Scholar
  28. Curtis, J. E.: Adoptive immunotherapy in the treatment of advanced malignant melanoma (abstract). Proc. Amer. Ass. Cancer Res. 12, 52 (1971).Google Scholar
  29. Czajowski, N. P., Rosenblatt, M., Wolf, P. L., Van Quaz, J.: A new method for active immunization to autologous human tumour tissue. Lancet 1967 II, 905.Google Scholar
  30. Das Gupta, T., Brasefield, R.: Metastatic melanoma — A clinicopathological study. Cancer (Philad.) 17, 1323–1339 (1964).Google Scholar
  31. Dawson, J. W.: The melanomata — A histological and clinical study. Edinb. med. J. 32, 502–732(1925).Google Scholar
  32. De Vries, J. E., Rümke, P., Bernheim, J. L.: Cytotoxic lymphocytes in melanoma patients. Int. J. Cancer 9, 567–576 (1972).Google Scholar
  33. Dorsey, C. S., Montgomery, H.: Blue naevus and its distinction from Mongolian spot and the naevus of OTA. J. invest. Derm 22, 225 (1954).PubMedGoogle Scholar
  34. Dubreuilh, M. W.: Lentigo malin des Vieillards. Ann. Derm. Syph. (Paris) 5, 1092 (1892).Google Scholar
  35. Dubreuilh, M. W.: De la melanose circonstrite pré-cancéreuse. Ann. Derm. Syph. (Paris) 3, 129 (1912).Google Scholar
  36. Eberman, A. A.: Beitrag zur Casristik de melanotischen Geschwulste. Dtsch. Z. Furchior 14, 498–526 (1896).Google Scholar
  37. Eiselt, T.: Nefer pigment krebs. Viertebjahvsch f.d. praktische Heilkunde 70, 87–107 (1861).Google Scholar
  38. Essex, M., Klein, G., Snyder, S. P., Harrold, J. P.: Feline sarcoma virus induced tumours: correlation between humoral antibody and tumour regression. Nature (Lond.) 233, 195–196 (1971).Google Scholar
  39. Evans, R., Alexander, P.: Role of macrophages in tumour immunity. Immunology 23, 615–636 (1972).PubMedGoogle Scholar
  40. Eve, F.: Lecture on melanoma. London Practitioner, 165–174 (1903).Google Scholar
  41. Everson, J. C., Cole, W. H.: Spontaneous regression of cancer. Philadelphia and London: W. B. Saunders Co. 1966.Google Scholar
  42. Ewing, J.: Neoplastic diseases. Philadelphia: W. B. Saunders Co. 1922.Google Scholar
  43. Fass, L., Herberman, R. B., Ziegler, J. L., Kiryabwire, J. W. M.: Cutaneous hypersensitivity reactions to autologous extracts of malignant melanoma cells. Lancet 1970 I, 116–118.Google Scholar
  44. Fedderman, J. L., Lewis, M. G., Clark, W. H., Egerer, I., Sarifn, L. K.: Tumour associated antibodies in the serum of occular melanoma patients. (Paper in preparation) (1973).Google Scholar
  45. Fergusson, A: Recurrence of melanotic tumour following removal. Lancet 1851 I, 622.Google Scholar
  46. Finney, J. W., Byers, E. H., Wilson, R. H.: Studies in tumour autoimmunity. Cancer Res. 20, 351 (1969).Google Scholar
  47. Flatt, R. F., Nelson, L. R., Middleton, C. C.: Melanotic lesions in the internal organs of miniature swine. Arch. Path. 93, 71–75 (1972).PubMedGoogle Scholar
  48. Foley, E. J.: Antigenic properties of methyl cholanthrene induced tumours in mice in the strain of origin. Cancer Res. 13, 835–837 (1953).PubMedGoogle Scholar
  49. Fortner, J. G., Mahy, A. G., Schrodt, G. R.: Transplantable tumours of the Syrian (golden) hamster. Cancer Res. 21, 161–229 (1961).PubMedGoogle Scholar
  50. Fossati, G., Colnaghi, M. E., Della Porta, G., Cascinelli, N., Veronesi, U.: Cellular and humoral immunity against malignant melanoma. Brit. med. J. 1971 II, 305–310.Google Scholar
  51. Ghose, T., Cerini, M., Carter, M., Nairn, R. C.: Immunoradioactive agent against cancer. Brit. med. J. 1967, I 90–93.Google Scholar
  52. Ghose, T., Norvell, S. T., Guclu, A., Cameron, D., Bodurtha, A., Mac Donald, A. S.: Immunochemotherapy of cancer with chlorambucil carrying antibody. Brit. med. J. 1972, 495–499.Google Scholar
  53. Gold, P.: Circulating antibodies against carcinoembryonic antigen of the human digestive system. Cancer (Philad.) 20, 1663 (1967).Google Scholar
  54. Gold, P., Freedman, S.: Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. exp. Med. 121, 439(1965).PubMedGoogle Scholar
  55. Gordon, M.: Effects of five primary genes on the site of melanomas in fishes and the influence of two color genes on their pigmentation. The biology of melanomas. N. Y. Acad. Sci. IV, 216–254 (1948).Google Scholar
  56. Hamilton-Fairley, G.: Immunity to malignant disease in man. Brit. med. J. 1969 II, 467.Google Scholar
  57. Handley, W. S.: The pathology of melanotic growths. Lancet 1907, I, 927–996.Google Scholar
  58. Harding, H. E., Passey, R. D.: A transplantable melanoma of the mouse. J. Path. Bact. 33, 417–427 (1930).Google Scholar
  59. Hellstrom I.: C. colony inhibition technique for demonstration of tumour cell destruction by lymphoid cells in vitro. Int. J. Cancer 2, 65–68 (1967).PubMedGoogle Scholar
  60. Hellstrom, I., Hellstrom, K. E.: Some recent studies on cellular immunity to human melanomas. Fed. Proc. (In press) (1973).Google Scholar
  61. Hellstrom, L, Hellstrom, K. E., Pierce, G. E., Yang, J. P. S.: Cellular and humoral immunity in different types of human neoplasm. Nature (Lond.) 220, 1352–1354 (1968).Google Scholar
  62. Hellstrom, I., Hellstrom, K. E., Sjögren, H. O., Warner, G. A.: Demonstration of cell-mediated immunity and human neoplasms of various histological types. Int. J. Cancer I, 1–16 (1971).Google Scholar
  63. Hellstrom, I., Hellstrom, K. E., Sjögren, H. O., Warer, G. A.: Destruction of cultivated melanoma cells by lymphocytes from healthy black (North American negro) donors. Int. J. Cancer (Philad.) 11, 116–122 (1973).Google Scholar
  64. Hellstrom, I., Sjögren, H. O., Warner, G., Hellstrom, K. E.: Blocking of cell-mediated tumour immunity by sera from patients with growing neoplasms. Int. J. Cancer 1, 226–237 (1971).Google Scholar
  65. Hjerpe, C. A., Theilen, G. H.: Malignant melanoma in porcine littermates. J. Amer. vet. med. Ass. 144, 1129–1131 (1964).PubMedGoogle Scholar
  66. Hughes, L. E., Kearney, B., Tully, M.: A study in clinical cancer immunotherapy. Cancer (Philad.) 26, 269–278 (1970).Google Scholar
  67. Hughes, L. E., Lytton, B.: Antigenic properties of human tumours: delayed cutaneous hypersensitivity reactions. Brit. med. J. 1964 I 209–212.Google Scholar
  68. Humphrey, L. J., Jewell, W. R., Murray, D. R.: Immunotherapy for the patient with cancer. Ann. Surg. 173, 47–54 (1971).PubMedGoogle Scholar
  69. Hunter-Craig, I., Newton, K. A., Westbury, G., Lacey, B. W.: Use of vaccinia virus in the treatment of metastatic malignant melanoma. Brit. med. J. 1970 II, 512–515.Google Scholar
  70. Hutchinson, J.: Senile freckles. Arch. Surg. 3, 318 (1892).Google Scholar
  71. Hutchinson, J.: Lentigo melanosis. Arch. Surg. 5, 252 (1894).Google Scholar
  72. Ikonopisov, R. L., Lewis, M. G., Hunter-Craig, I. D., Bodenham, D. C., Phillips, T. M., Cooling, I. C., Procter, J., Hamilton-Fairley, G., Alexander, P.: Auto-immunization with irradiated tumour cells in human malignant melanoma. Brit. med. J. 1970 II, 752-Google Scholar
  73. Jehn, D., Nathanson, L., Schwartz, R. S.: In vitro lymphocyte stimulation by a soluble tumour antigen in malignant melanoma. New. Engl. J. Med. 283, 329–333 (1970).PubMedGoogle Scholar
  74. Klavins, J. V., Mesa-Tejada, R., Wteiss, M.: Human carcinoma antigens cross reacting with anti-embryonic antibodies. Nature (Lond.) New Biology 234, 153–154 (1971).Google Scholar
  75. Klein, E.: Hypersensitivity reaction at tumour site. Cancer Res. 29, 2351–2362 (1969).PubMedGoogle Scholar
  76. Klein, E.: Chemotherapy and immunotherapy for cancer involving the skin. Cancer (Philad.) (to be published) (1973).Google Scholar
  77. Klein, G., Clifford, P., Klein, E., Stjernsward, J.: Search for tumour specific immune reactions in Burkitt’s lymphoma patients by the membrane immunofluorescence reaction. Proc. nat. Acad. Sci. (Wash.) 55, 1628 (1966).Google Scholar
  78. Krementz, E. T., Goodwin, D. P., Samuels, M. S., Hornung, M. D., Benes, E. N.: Immunological approaches to the management of malignant melanoma in “Melanoma and Skin Cancer”. Proc. of Int. Cancer Conf., Sydney, Australia. p. 473–495. Sydney, N. S. Wales, Australia: V. C. N. Blight, Government Printer 1972.Google Scholar
  79. Krementz, E. T., Samuels, M. S., Wallace, J. H., Benes, E. N.: Clinical experiences in immunotherapy of cancer. Surg. Gynec. Obstet. 133, 209–217 (1971).PubMedGoogle Scholar
  80. Kopf, A. W.: Host defenses against malignant melanoma. Hospital Practice, Oct. 1971, 116–124.Google Scholar
  81. Laennec, R. J. H.: La Melanose. Bul. de Fac. de Med. de Paris 2, (1806).Google Scholar
  82. Lejeune, F.: Macrophages in malignant melanoma. Yale J. of Biol. and Med. Proc. of Pigmented Cell Biology Conf., Yale, Jan. 1973 (in press).Google Scholar
  83. Lennox, B.: The histopathology of tumours — melanomata. Recent advances in pathology, 7th. ed., p. 17–24. London: J. A. Churchill Ltd. 1960.Google Scholar
  84. Levene, A.: The comparative pathology of skin tumours of horse, dog and rat compared with man with special reference to tumours of melanocytic origin. Melanoma and Skin Cancer. Proc. of Int. Cancer Conf., Sydney, Australia. Sydney, N. S. Wales, Australia: V. C. N. Blight, Government Printer 1972.Google Scholar
  85. Lewis, M. G.: Possible immunological factors in human malignant melanoma. Lancet 1967 II, 921–922.Google Scholar
  86. Lewis, M. G.: Malignant melanoma in Uganda. M. D. Thesis, University of London (1968).Google Scholar
  87. Lewis, M. G.: Immunological studies in patients with malignant melanoma — The role of circulating antibodies. “Melanoma and Skin Cancer”, p. 233–256. Proc. of Int. Cancer Conf., Sydney, Australia. N. S. Wales, Australia: V. C. N. Blight, Government Printer 1972.Google Scholar
  88. Lewis, M. G.: Tumour specific antigens in melanoma. Proc. of Seventh Cancer Conf. J. B. Lippincott Co. Philadelphia: (1973a).Google Scholar
  89. Lewis, M. G.: Proc. Symposium on the Cell and Cancer. Royal College of Pathology, London, Jan. 1973. To be published — Suppl. J. clin. Path. (1973b).Google Scholar
  90. Lewis, M. G.: Melanoma in recent advances in cancer research. Ed. Templeton, A. C., vol. 41, ch. 9 (in press). Berlin-Heidelberg-New York: Springer 1973c.Google Scholar
  91. Lewis, M. G., Avis, P. J. G., Phillips, T. M., Sheikh, K. M. A.: Tumour specific and tumour associated antigens in human malignant melanoma. Proc. of Pigmented Cell Biology Conf., Yale Univ. Yale J. Biol. Med. (in press 1973).Google Scholar
  92. Lewis, M. G., Copeman, P.: Halo Naevus — A frustrated malignant melanoma? Brit. med. J. 1972, II, 47–48.Google Scholar
  93. Lewis, M. G., Humble, J. G., Stanley Lee, E., Phillips, T. M.: The effects of intravenous phytohaemagglutinin in a patient with disseminated malignant melanoma. Europ. J. Clin. Biol. Res. 16, 924–927 (1971).Google Scholar
  94. Lewis, M. G., Ikonopisov, R. L., Nairn, R. C., Phillips, T. M., Hamilton-Fairley, G., Bodenham, D. C., Alexander, P.: Tumour specific antibodies in human malignant melanoma and their relationship to the extent of the disease. Brit. med. J. 1969, 547–552.Google Scholar
  95. Lewis, M. G., Kiryabwire, J. W. M.: Malignant melanoma in Uganda — Aspects of behaviour and natural history. Cancer (Philad.) 21, 876 (1968).Google Scholar
  96. Lewis, M. G., Loughbridge, L. W., Phillips, T. M.: Immunological studies on a patient with the nephrotic syndrome associated with malignancy of non-renal origin. Lancet 1971 II, 134.Google Scholar
  97. Lewis, M. G., McCloy, E., Blake, J.: The significance of circulating antibody in the localization of human malignant melanoma. Brit. J. Surg. 60, 443–446 1973).PubMedGoogle Scholar
  98. Lewis, M. G., Phillips, T. M.: The specificity of surface membrane immunofluorescence in human malignant melanoma. Int. J. Cancer 10, 105–111 (1972a).PubMedGoogle Scholar
  99. Lewis, M. G., Phillips, T. M.: Separation of two distinct tumour associated antibodies in the serum of melanoma patients. J. nat. Cancer Inst. 49, 915–917 (1972b).PubMedGoogle Scholar
  100. Lewis, M. G., Phillips, T. M., Cook, K. B., Blake, J.: Possible explanation for loss of detectable antibody in patients with disseminated malignant melanoma. Nature (Lond.) 232, 52–54 (1971).Google Scholar
  101. Little, J. H.: Histology and prognosis in cutaneous malignant melanoma. In: Melanoma and Skin Cancer. Proc. of Int. Cancer Conf., Sydney, Australia. Sydney, N. S. Wales, Australia: V. C. N. Blight, Government Printer 1972.Google Scholar
  102. Little, J. H., Davis, N. C.: The classification of melanoma. Med. J. Aust. — correspondence — 2, 1028 (1969).Google Scholar
  103. Loughbridge, L. W., Lewis, M. G.: Nephrotic syndrome in malignant disease of nonrenal origin. Lancet 1971 I, 256.Google Scholar
  104. MacDonald, E. J.: Epidemiology of melanoma. Ann. N. Y. Acad. Sci. 100, 4–17 (1963).Google Scholar
  105. Mackie, R. M., Carfrae, E. M., Cochram, A. J.: Assessment of prognosis in malignant melanoma. Lancet 2, 601 (1972).Google Scholar
  106. McBride, C. M., Bowen, J. M., Dmochowski, L.: Antinucleolar antibodies in the sera of patients with malignant melanoma. Surg. Forum 23, 92–93 (1972).PubMedGoogle Scholar
  107. McGovern, V.: The classification of melanoma and its relationship with prognosis. Pathology 2, 85 (1970).PubMedGoogle Scholar
  108. McGovern, V. J.: Melanoma; Growth patterns, multiplicity and regression. In: Melanoma and Skin Cancer. Proc. of Int. Cancer Conf., Sydney. Aust. Sydney, N. S. Wales, Australia: V. C. N. Blight, Government Printer 1972.Google Scholar
  109. McKenna, J. M., Sanderson, R. P., Blakemore, W. S.: Studies of antigens of human tumours — I. Demonstration of a soluble specific antigen in HeLa cells and some human tumours. Cancer Res. 24, 754 (1964).PubMedGoogle Scholar
  110. Millikan, L. E.: Melanoma in miniature swine. Proc. Yale Pigmented Cell Biol. Conf. Yale J. Med. Biol. (1973).Google Scholar
  111. Milton, G. W., Lane-Brown, M. M.: The limited role of attenuated smallpox virus in the management of advanced malignant melanoma. Aust. N. Z. J. Surg. 35, 286–290 (1966).PubMedGoogle Scholar
  112. Moore, G. E., Gerner, R. E.: Malignant Melanoma: Surg. Gynec. Obstet. 132, 427 (1971).Google Scholar
  113. Morton, D. L., Eilber, F. R., Malmgren, R. A.: Immune factors in cancer: Malignant melanomas; Skeletal and soft tissue sarcomas. Prog. exp. Tumor Res. (Basel) 14, 25–42 (1971).Google Scholar
  114. Morton, D. L., Eilber, F. R., Malmgren, R. A., Wood, W. C.: Immunological factors which influence response in immunotherapy in malignant melanoma. Surgery 64, 233–240 (1970).Google Scholar
  115. Morton, D. L., Malmgren, R. A., Holmes, E. C., Ketcham, A. S.: Demonstration of antibodies against human malignant melanoma by immunofluorescence. Surgery 64, 233–240 (1968).PubMedGoogle Scholar
  116. Muna, N. M., Marcus, S., Smart, C.: Detection by immunofluorescence of antibodies specific for human malignant melanoma. Cancer (Philad.) 23, 88–93 (1969).Google Scholar
  117. Nadler, S. H., Moore, G. E.: Immunotherapy of malignant disease. Arch. Surg. 99, 376–381 (1969).PubMedGoogle Scholar
  118. Nagel, G. A.: Immunite cellulaire du melanome. Rev. de L’inst. Pasteur de Lyon 3, 207–217 (1970).Google Scholar
  119. Nagel, G. A., Arnault, G. St., Holland, J. F., Kirkpatrick, D.: Kirkpatrick, R.: Cell-mediated immunity against malignant melanoma in monozygous twins. Cancer Res. 30, 1828–1832 (1970).PubMedGoogle Scholar
  120. Nagel, G. A., Piessens, W. F., Stilmant, M. M., Lejeune, F.: Evidence for tumour specific immunity in human malignant melanoma. Europ. J. Cancer 7, 41 (1971).Google Scholar
  121. Nairn, R. C.: Fluorescent protein tracing. 3rd. ed. London: E. & S. Livingstone & Co. Ltd. 1969.Google Scholar
  122. Nairn, R. C., Nind, A. P. P., Guli, E. P. G., Muller, H. K., Rolland, J. M., Minty, C. C. J.: Specific immune response in human skin carcinoma. Brit. med. J. 1971, 701–705.Google Scholar
  123. Nathanson, L.: Experience with BCG in malignant melanoma (abstract). Proc. Amer. Ass. Cancer Res. 12, 99 (1971).Google Scholar
  124. Nathanson, L., Jehn, V., Schwartz, R. S.: Disappearance of a tumour-associated antigen in malignant melanoma after imidazole carboxamide therapy. Cancer (Philad.) 27, 411–415 (1971).Google Scholar
  125. Olsen, G.: The malignant melanoma of the skin. New theories based on a study of 500 cases. Acta chir. scand. (suppl.) 365, 222 (1966).Google Scholar
  126. Pack, G. T.: A clinical study of pigmented nevi and melanomas. The biology of melanoma. N. Y. Acad. Sci. IV, 52–81 (1948).Google Scholar
  127. Pack, G. T. (1950).Google Scholar
  128. Higgins and Pack(1951) Quoted from Nagel G. A., W. F. Piessons, M. M. Stilmantand F. Lejeune: Evidence for tumour specific immunity in human malignant melanoma. Europ. J. Cancer 7, 41 (1971).Google Scholar
  129. Phillips, T. M.: Immunofluorescent techniques in the study of malignant melanoma. Rev. de L’inst. Pasteur du Lyon 4, 331–337 (1971).Google Scholar
  130. Phillips, T. M., Lewis, M. G.: A system of immunofluorescence in the study of tumour cells. Rev. Europ. etudes Clin. Biol. 15, 1016–1020 (1970).Google Scholar
  131. Piessons, W.: Evidence for human cancer immunity. A review. Cancer (Philad.) 26, 1212–1220 (1970).Google Scholar
  132. Prehn, R. T., Main, J. M.: Immunity to methyl cholanthrene induced sarcomas. J. nat. Cancer Inst. 18, 769–778 (1957).PubMedGoogle Scholar
  133. Proctor, J. W., Rudenstram, C. M., Alexander, P.: A factor preventing the development of lung metastases in rats with sarcomas. Nature (Lond.) (in press) (1973).Google Scholar
  134. Pulvertaft, R. J.V.: The examination of pathological tissues in a fresh state. In: Modern trends in pathology, p. 19–44, ed. D. H. Collins, London: Butterworth 1959.Google Scholar
  135. Rhomsdahl, M. M., Cox, I. S.: Human malignant melanoma antibodies demonstrated by immunofluorescence. Arch. Surg. 100, 491–497 (1970).Google Scholar
  136. Savel, H.: Effects of autologous tumour extracts on cultivated human peripheral blood lymphocytes. Cancer (Philad.) 24, 56–63 (1969).Google Scholar
  137. Siegler, H. F., Shingleton, W. W., Metzgar, R. S., Buckley, C. E., Bergog, P. M., Miller, D. S., Fetler, B. F., Phaup, M. B.: Non-specific and specific immunotherapy in patients with melanoma. Surgery 72, 162–174 (1972).Google Scholar
  138. Simmons, R. L.: Quoted by Morton, D. L., C. M. Haskel, Y. H. Pilch, F. C. Sparksand W. D. Winters: Recent advances in oncology. UCLA Conference. Ann. intern. Med. 77, 431–454 (1972).Google Scholar
  139. Sjögren, H. O., Hellstrom, I., Bansal, S. C., Hellstrom, K. E.: Suggestive evidence that the blocking antibodies of tumour bearing individuals may be antigen-antibody complexes. Proc. nat. Acad. Sci. (Wash.) 68, 1372–1375 (1971).Google Scholar
  140. Smith, J. L. Jr., Stehlin, J. S. Jr.: Spontaneous regression of primary malignant melanoma with regional metastases. Cancer (Philad.) 18, 1399–1415 (1965).Google Scholar
  141. Steward, T. H. M.: The presence of delayed hypersensitivity reactions in patients towards cellular extracts of their malignant tumours. Cancer (Philad.) 23, 1368–1387 (1969).Google Scholar
  142. Sumner, W. C., Foraker, A. G.: Spontaneous regression of human melanoma — clinical and experimental studies. Cancer (Philad.) 13, 79–81 (1960).Google Scholar
  143. Sutton, R. L.: An unusual variety of vitiligo; Leucoderma acquisitium centrifugium. J. cutan. Dis. 34, 797–800 (1916).Google Scholar
  144. Telmourian, B., McCune, W. S.: Surgical management of malignant melanoma. Amer. Surg. 29, 529–532 (1963).Google Scholar
  145. The, T. H., Eibergen, R., Lamberts, H. B., Oldhoff, J., Vonderploeg, E., Scaraford-Koops, H., Nieweg, H. O.: Immune phagocytosis in vivo of human malignant melanoma cells. Acta med. scand. 192, 141–144 (1972).PubMedGoogle Scholar
  146. Todd, D. W., Spencer-Payne, W., Farrow, G. M., Winklemann, R. K.: Spontaneous regression of primary malignant melanoma with regional metastases: Report of a case with photographic documentation. Proc. Mayo Clin. 41, 10 (1966).Google Scholar
  147. Urteaga, O. B., Pack, G. T.: On the antiquity of melanoma. Cancer (Philad.) 19, 607–611 (1966).Google Scholar
  148. Van den Brenk, H. A. S.: Autoimmunization in human malignant melanoma. Brit. med. J. 1969, 171.Google Scholar
  149. Wardrop, J.: Baillies morbid anatomy, p. LII–LV. London: Longman 1830.Google Scholar
  150. Whitehouse, J. M., Holborow, E. S.: Smooth muscle antibody in malignant disease. Brit. med. J. 1971, 511–613.Google Scholar
  151. Wilbur, D. L., Hartmann, H. P.: Malignant melanoma with delayed metastatic growth. Ann. intern. Med. 5, 201–211 (1931).Google Scholar
  152. Ziegler, J. L., Lewis, M. G., Luyomboya, J. M. S., Kiryabwire, J. W. M.: Immunologic studies on patients with malignant melanoma in Uganda. Brit. J. Cancer 23, 729–734 (1969).PubMedGoogle Scholar

Copyright information

© Springer-Verlag, Berlin · Heidelberg 1974

Authors and Affiliations

  • Martin G. Lewis

There are no affiliations available

Personalised recommendations